Pamela Mrad

Pamela Mrad

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2019 in Community Mental Health Journal
Verified
Journal Article
Closed access
PDF file
NHNadine Hamieh
Nadine Hamieh
ESEman Sharara
Eman Sharara
NSNoura Salibi
Noura Salibi
PMPamela Mrad
Pamela Mrad
MCMonique Chaaya
Monique Chaaya

11 October 2021 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
NHNadine Haddad
Nadine Haddad
HCHannah Clapham
Hannah Clapham
HNHala Abou Naja
Hala Abou Naja
MSMajd Saleh
Majd Saleh
ZFZeina Farah
Zeina Farah
NHNatasha Howard
Natasha Howard
Introduction: The first detected case in Lebanon on 21 February 2020 engendered implementation of a nationwide lockdown alongside timely contact-tracing and testing. Objectives: Our study aims to calculate the serial interval of SARS-CoV-2 using contact tracing data collected 21 February to 30 June 2020 in Lebanon to guide testing strategies. Methods: rRT-PCR positive COVID-19 cases reported to the Ministry of Public Health Epidemiological Surveillance Program (ESU-MOH) are rapidly investigated and identified contacts tested. Positive cases and contacts assigned into chains of transmission during the study time-period were verified to identify those symptomatic, with non-missing date-of-onset and reported source of exposure. Selected cases were classified in infector–infectee pairs. We calculated mean and standard deviation for the serial interval and best distribution fit using AIC criterion. Results: Of a total 1788 positive cases reported, we included 103 pairs belonging to 24 chains of transmissions. Most cases were Lebanese (98%) and male (63%). All infectees acquired infection locally. Mean serial interval was 5.24 days, with a standard deviation of 3.96 and a range of − 4 to 16 days. Normal distribution was an acceptable fit for our non-truncated data. Conclusion: Timely investigation and social restriction measures limited recall and reporting biases. Pre-symptomatic transmission up to 4 days prior to symptoms onset was documented among close contacts. Our SI estimates, in line with international literature, provided crucial information that fed into national contact tracing measures. Our study, demonstrating the value of contact-tracing data for evidence-based response planning, can help inform national responses in other countries.

14 June 2023 in Epidemiologia
Verified
Journal Article
Open access
PDF file
ZFZeina Farah
Zeina Farah
NHNadine Haddad
Nadine Haddad
HNHala Abou El Naja
Hala Abou El Naja
MSMajd Saleh
Majd Saleh
PMPamela Mrad
Pamela Mrad
NGNada Ghosn
Nada Ghosn
In Lebanon, the nationwide vaccination against COVID-19 was launched in February 2021 using the Pfizer-BioNTech vaccine and prioritizing elderly people, persons with comorbidities, and healthcare workers. Our study aims to estimate the post-introduction vaccine effectiveness (VE) of the Pfizer-BioNTech vaccine in preventing COVID-19 hospitalizations among elderly people ≥75 years old in Lebanon. A case–control study design was used. Case patients were Lebanese, ≥75 years old, and hospitalized with positive PCR results during April–May 2021, and randomly selected from the database of the Epidemiological Surveillance Unit at the Ministry of Public Health (MOPH). Each case patient was matched by age and locality to two controls. The controls were hospitalized, non-COVID-19 patients, randomly selected from the MOPH hospital admission database. VE was calculated for fully (2 doses ≥14 days) and partially vaccinated (≥14 days of the first or within 14 days of the second dose) participants using multivariate logistic regression. A total of 345 case patients and 814 controls were recruited. Half were females, with a mean age of 83 years. A total of 14 case patients (5%) and 143 controls (22%) were fully vaccinated. A bivariate analysis showed a significant association with gender, month of confirmation/hospital admission, general health, chronic medical conditions, main income source, and living arrangement. After adjusting for a month of hospital admission and gender, the multivariate analysis yielded a VE of 82% (95% CI = 69–90%) against COVID-19-associated hospitalizations for those fully vaccinated and 53% (95% CI = 23–71%) for those partially vaccinated. Our study shows that the Pfizer-BioNTech vaccine is effective in reducing the risk for COVID-19-associated hospitalizations of Lebanese elderly people (≥75 years old). Additional studies are warranted to explore VE in reducing hospitalizations for younger age groups, as well as reducing COVID-19 infections.

24 January 2022 in medRxiv
Verified
Preprint
Open access
PDF file
ZFZeina Farah
Zeina Farah
NHNadine Haddad
Nadine Haddad
HNHala Abou El Naja
Hala Abou El Naja
MSMajd Saleh
Majd Saleh
PMPamela Mrad
Pamela Mrad
NGNada Ghosn
Nada Ghosn
Introduction In Lebanon, the nationwide vaccination against COVID-19 was launched in February-2021 using Pfizer-BioNTech vaccine and prioritizing elderly, persons with comorbidities and healthcare workers. Our study aims to estimate the post-introduction vaccine effectiveness (VE) of Pfizer-BioNTech in preventing COVID-19 hospitalization among ≥75 years in Lebanon. Methods A case-control study design was used. Cases were Lebanese, ≥75 years and hospitalized with positive PCR result during April-May 2021. Cases were randomly selected from the COVID-19 database of the Epidemiological Surveillance Unit(ESU) at the Ministry of Public Health(MOPH). Each case was matched by age and locality to 2 controls. Controls were hospitalized, non-COVID-19 patients with negative PCR result, randomly selected from the MOPH hospital admission database. VE was calculated for fully and partially vaccinated, using multivariate conditional logistic regression analyses. Results 345 cases and 814 controls were recruited. Half were females, with a mean age of 83 years. 14 cases(5%) and 143 controls(22%) were fully vaccinated. Bivariate analysis showed significant association with: gender, month of confirmation/admission, general health, chronic medical conditions, main income source and living arrangement. After adjusting for month of admission and gender, multivariate analysis yielded a VE of 82% (95%CI = 69%-90%) against COVID-19 associated hospitalization for those fully vaccinated and 53% (95%CI = 23%-71%) for those partially vaccinated (≥14 days of first or within 14 days of second dose). Conclusions Our study showed that Pfizer-BioNTech vaccine is effective in reducing risk for COVID-19– associated hospitalization in Lebanese elderly(≥75 years). Additional studies are warranted to explore vaccine effectiveness in reducing hospitalization in younger age groups, as well as in reducing covid-19 infections.